印度在喀拉拉邦启动了一个新的生物技术设施,以促进药物发现和细胞疗法,这是将生物经济发展到3 000亿美元的国家动力的一部分。 India launched a new biotech facility in Kerala to boost drug discovery and cell therapies, part of a national push to grow the bioeconomy to $300 billion.

联盟部长Jitendra Singh在喀拉拉邦Thiruvananthapuram的BRIC-RGCB,为新的重组细胞和感应器中央设施揭幕,并为国家科学日时在Kerala的Thiruvananthapuram的BRIC-RGCB80 crore GMP设施打下了基础。 Union Minister Jitendra Singh inaugurated a new Central Facility for Recombinant Cells and Sensors and laid the foundation for an ₹80 crore GMP facility at BRIC-RGCB in Thiruvananthapuram, Kerala, on National Science Day. 这些发展是印度推动生物驱动经济、支持药物发现、基因组学和CAR-T等细胞疗法的一部分。 Singh强调生物经济在十年内从100亿美元增长到1,660亿美元,目标是3,000亿美元,由BioE3和Biopharma SHAKTI计划等政策驱动。 The developments, part of India’s push toward a bio-driven economy, support drug discovery, genomics, and cell therapies like CAR-T. Singh highlighted the bioeconomy’s growth from $10 billion to $166 billion in a decade, with a target of $300 billion, driven by policies like BioE3 and the Biopharma SHAKTI Mission. 印度目前有超过11 000家生物技术创业企业,比2014年的约50家有所增加,反映出政府投资和私营部门的大力合作。 Over 11,000 biotech start-ups now operate in India, up from around 50 in 2014, reflecting strong government investment and private sector collaboration. 该设施设有数百条稳定的细胞线,用于癌症研究,并支持国家卫生举措,包括HPV疫苗接种。 The facility houses hundreds of stable cell lines for cancer research and supports national health initiatives, including HPV vaccination.